Evidence map›Paper›PMID 40740678›Full record

ReviewNeuroImmune pharmacology and therapeutics2025

Adaptive immunity in the pathogenesis and treatments of Parkinson's disease.

Xiaoqing Du, Samia Akter, Davina B Oludipe, Susmita Sil, Chen Zhang, Howard E Gendelman, R Lee Mosley

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in NeuroImmune pharmacology and therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaoqing DuDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Samia AkterDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Davina B OludipeDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Susmita SilDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Chen ZhangDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Howard E GendelmanDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
R Lee MosleyDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.ORCID https://orcid.org/0000-0002-4241-6149

Funding

Neuroprotective Immunity and HIV DementiaR01NS034239 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Howard E Gendelman, R Lee Mosley · 1995 to 2026
$12.3M
Targeted lipid nanoparticles for gene therapeutics delivery approach to eradicating HIV reservoirsR01MH121402 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Benson Edagwa, Howard E Gendelman · 2019 to 2026
$4.9M
NIMH NIH HHS R01 MH121402NINDS NIH HHS R01 NS034239
6 · The paper itself

Abstract

Neuroimmunity drives the pathophysiology of Parkinson's disease (PD). This disease affects both the central and peripheral nervous systems. The immune system is engaged through the progressive accumulation of alpha-synuclein (α-syn), a driver of immunity and a pathological hallmark of PD. Consequent α-syn-induced immune activation leads to neuronal damage. This leads not only to the activation of microglia within the central nervous system, but also to the recruitment and activation of peripheral immune cells that infiltrate the brain and contribute to a widespread immune response. Moreover, PD-associated genes and risk factors have been increasingly recognized as essential regulators of immune functions. This review summarizes the current understanding of adaptive immunity in PD and explores emerging immunomodulatory strategies that may inform future therapeutic development.

Indexed as

adaptive immunityalpha-synucleinParkinson’s disease

Identifiers

PMID40740678
PMCPMC12304880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.